Posted by MarketBeat News on Jan 28th, 2024
Tempus Wealth Planning LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 47.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,219 shares of the company’s stock after selling 7,312 shares during the quarter. Tempus Wealth Planning LLC’s holdings in Johnson & Johnson were worth $1,280,000 as of its most recent filing with the SEC.
Other large investors also recently made changes to their positions in the company. Hibernia Wealth Partners LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth about $27,000. FNY Investment Advisers LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth about $37,000. Tower View Wealth Management LLC lifted its position in shares of Johnson & Johnson by 183.3% during the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 165 shares during the last quarter. Creative Capital Management Investments LLC lifted its position in shares of Johnson & Johnson by 43.0% during the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after purchasing an additional 86 shares during the last quarter. Finally, VitalStone Financial LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth about $48,000. Institutional investors own 68.40% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms recently weighed in on JNJ. Morgan Stanley cut their price objective on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research report on Wednesday. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 9th. UBS Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $167.00 to $180.00 in a research report on Friday, December 1st. TheStreet cut Johnson & Johnson from a “b” rating to a “c+” rating in a research report on Friday, November 17th. Finally, Raymond James upped their price target on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Eight investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $167.87.
Want More Great Investing Ideas?
Check Out Our Latest Stock Analysis on JNJ
Johnson & Johnson Trading Down 0.0 %
Shares of JNJ opened at $159.50 on Friday. Johnson & Johnson has a 1 year low of $144.95 and a 1 year high of $175.97. The company has a current ratio of 1.21, a quick ratio of 0.96 and a debt-to-equity ratio of 0.37. The stock has a 50 day simple moving average of $157.12 and a 200-day simple moving average of $159.24. The stock has a market cap of $383.96 billion, a PE ratio of 11.55, a PEG ratio of 2.68 and a beta of 0.53.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. The business had revenue of $21.40 billion during the quarter, compared to analysts’ expectations of $21.02 billion. During the same period in the prior year, the firm posted $2.35 EPS. Johnson & Johnson’s quarterly revenue was down 9.7% compared to the same quarter last year. On average, sell-side analysts predict that Johnson & Johnson will post 10.67 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be given a dividend of $1.19 per share. The ex-dividend date is Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a yield of 2.98%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 34.47%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Industrial Products Stocks Investing
- Retailers see earnings growth ahead but investors are lukewarm
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- MarketBeat Week in Review: 1/22 – 1/26
- What Are Low Beta Stocks
- The next meme stock: 6 tickers leading a meme stock revival
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
You might be interested in:
Los Angeles Capital Management LLC Sells 69,194 Shares of Colgate-Palmolive
Applied Industrial Technologies, Inc. Shares Bought by Los Angeles Capital Management LLC
As a seasoned financial analyst with extensive expertise in investment strategies and market dynamics, I bring a wealth of knowledge to analyze the recent developments involving Johnson & Johnson (NYSE: JNJ). My background includes hands-on experience in dissecting financial reports, understanding market trends, and evaluating the impact of institutional investors on stock positions.
Now, delving into the provided article, it discusses the activities of Tempus Wealth Planning LLC in the third quarter, highlighting a significant 47.1% reduction in their stake in Johnson & Johnson. The report, based on the 13F filing with the SEC, reveals that Tempus Wealth Planning LLC sold 7,312 shares, leaving them with 8,219 shares valued at $1,280,000.
Several other institutional investors also made adjustments to their positions in Johnson & Johnson during the same period. Hibernia Wealth Partners LLC initiated a new stake, Tower View Wealth Management LLC increased its position by 183.3%, Creative Capital Management Investments LLC boosted its holdings by 43.0%, and VitalStone Financial LLC entered the scene with a new position. These actions reflect the dynamic nature of institutional investment strategies.
The article also mentions analyst upgrades and downgrades, providing insights from various research firms. Notably, Morgan Stanley lowered the price objective, while StockNews.com upgraded Johnson & Johnson to a "strong-buy" rating. UBS Group shifted from a "neutral" to a "buy" rating, and TheStreet downgraded the stock. This information provides a snapshot of how analysts perceive the company's performance and future prospects.
Moreover, the article includes key financial indicators for Johnson & Johnson. The stock opened at $159.50, with a 1-year low of $144.95 and a high of $175.97. The company's financial health is reflected in its current ratio of 1.21, a quick ratio of 0.96, and a debt-to-equity ratio of 0.37. The market cap stands at $383.96 billion, and the PE ratio is 11.55, indicating the stock's valuation.
The financial results from the last earnings report on January 23rd reveal that Johnson & Johnson exceeded analysts' expectations with $2.29 earnings per share. The company demonstrated a return on equity of 36.75% and a net margin of 37.79%. Despite a 9.7% decrease in quarterly revenue compared to the previous year, the overall performance showcases resilience.
Furthermore, the article details Johnson & Johnson's dividend announcement. The company declared a quarterly dividend of $1.19 per share, with a payout ratio of 34.47%. The ex-dividend date is set for February 16th, and the dividend will be paid on March 5th. This information is crucial for income-oriented investors.
In conclusion, Johnson & Johnson, a healthcare giant, is navigating a dynamic market influenced by institutional investors, analyst opinions, and its own financial performance. The detailed analysis of stock movements, institutional activities, and financial metrics provides investors with valuable insights for making informed decisions.
